Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 5;379(1):64-73.
doi: 10.1056/NEJMra1706169.

Chimeric Antigen Receptor Therapy

Carl H June  1 , Michel Sadelain  1
Affiliations
Review

Chimeric Antigen Receptor Therapy

Carl H June et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Chimeric Antigen Receptor (CAR) T Cells Engrafting, Trafficking to Tumor, and Proliferating Extensively after Infusion.
After infusion, CAR T cells leave the blood and travel to sites of tumor, where they identify and kill tumor cells. This can trigger extensive proliferation of CAR T cells and the release of tumor antigens, which activates the immune system to recruit non–CAR T cells, thus eliciitng further antitumor responses in a process known as cross priming.
Figure 2.
Figure 2.. Structure of CARs and T-Cell Receptors.
Panel A shows the structure of a T-cell receptor, which consists of heterodimeric and antigen-specific α and β chains that closely associate with the invariant ε, δ, γ, and ζ chains of the CD3 complex. The T-cell receptor binds to the HLA allele that has a bound peptide derived from a tumor antigen on the target cell. Panel B shows the CAR, which includes the single-chain variable fragment (scFv) that binds to tumor antigens, fused to a spacer and transmembrane domain. The intracellular domain contains costimulatory domains, such as CD28 and 4–1BB and the CD3ζ chain, which drive signal activation and amplification of CAR T cells. S–S denotes disulfide bond.
See this image and copyright information in PMC

Comment in

  • A Look Forward - The Frontiers in Medicine Series.
    Caulley L, Ramaswami R, Longo DL, Phimister EG, Ingelfinger JR, Ropper AH, Stern K, Burke AE, Knoper KM, Seals JJJ, Müller DC, Drazen JM. Caulley L, et al. N Engl J Med. 2018 Jul 5;379(1):85-86. doi: 10.1056/NEJMe1806084. N Engl J Med. 2018. PMID: 29972760 No abstract available.

References

    1. Hoos A. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016;15:235–47. - PubMed
    1. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928–43. - PubMed
    1. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217–21. - PMC - PubMed
    1. Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci 1954;143:58–80. - PubMed
    1. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955;102: 157–77. - PMC - PubMed

MeSH terms